Nkarta, Inc. (NKTX) Current Ratio
- Current ratio · latest quarter: Value 7.98×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.98× | Current assets / current liabilities. $188.04M ÷ $23.56M ≈ 7.98× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 188.04M USD | Assets, Current |
| Current obligations | 23.56M USD | Liabilities, Current |
| Cash and equivalents | 24.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.82M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $188.04M | $23.56M | $24.96M | (m) | (m) | (m) | $3.82M | (m) | 7.98× |
| 2026-03-31 | $235.88M | $18.21M | $27.36M | (m) | (m) | (m) | $1.59M | (m) | 12.96× |
| 2025-12-31 | $282.51M | $22.27M | $39.63M | (m) | (m) | (m) | $2.09M | (m) | 12.69× |
| 2025-09-30 | $289.27M | $18.99M | $60.11M | (m) | (m) | (m) | $1.44M | (m) | 15.23× |
| 2025-06-30 | $296.57M | $18.93M | $53.41M | (m) | (m) | (m) | $1.51M | (m) | 15.67× |
| 2025-03-31 | $271.55M | $18.76M | $52.60M | (m) | (m) | (m) | $1.49M | (m) | 14.48× |
| 2024-12-31 | $273.34M | $18.92M | $27.87M | (m) | (m) | (m) | $638.00K | (m) | 14.45× |
| 2024-09-30 | $290.15M | $22.47M | $56.96M | (m) | (m) | (m) | $1.94M | (m) | 12.91× |
| 2024-06-30 | $331.80M | $20.86M | $120.40M | (m) | (m) | (m) | $3.76M | (m) | 15.91× |
| 2024-03-31 | $442.78M | $22.19M | $250.28M | (m) | (m) | (m) | $3.18M | (m) | 19.95× |
| 2023-12-31 | $253.07M | $23.33M | $31.04M | (m) | (m) | (m) | $3.67M | (m) | 10.85× |
| 2023-09-30 | $281.19M | $25.64M | $38.26M | (m) | (m) | (m) | $4.28M | (m) | 10.97× |
| 2023-06-30 | $286.74M | $26.61M | $29.12M | (m) | (m) | (m) | $3.01M | (m) | 10.77× |
| 2023-03-31 | $332.19M | $25.98M | $53.67M | (m) | (m) | (m) | $5.41M | (m) | 12.79× |
| 2022-12-31 | $360.69M | $22.05M | $37.49M | (m) | (m) | (m) | $1.76M | (m) | 16.36× |
| 2022-09-30 | $400.92M | $26.43M | $39.65M | $352.70M | (m) | (m) | $9.49M | (m) | 15.17× |
| 2022-06-30 | $417.38M | $13.18M | $131.65M | $281.31M | (m) | (m) | $2.97M | (m) | 31.66× |
| 2022-03-31 | $223.22M | $10.84M | $41.61M | $175.35M | (m) | (m) | $2.02M | (m) | 20.59× |
| 2021-12-31 | $245.78M | $12.94M | $60.82M | $177.27M | (m) | (m) | $1.11M | (m) | 18.99× |
| 2021-09-30 | $264.64M | $12.05M | $96.22M | $161.48M | (m) | (m) | $2.14M | (m) | 21.96× |
| 2021-06-30 | $283.94M | $10.26M | $24.42M | $255.38M | (m) | (m) | $2.16M | (m) | 27.68× |
| 2021-03-31 | $302.23M | $9.35M | $62.61M | $236.66M | (m) | (m) | $2.01M | (m) | 32.31× |
| 2020-12-31 | $318.83M | $8.83M | $96.69M | $218.22M | (m) | (m) | $1.18M | (m) | 36.10× |
| 2020-09-30 | $333.39M | $9.56M | $188.57M | $141.19M | (m) | (m) | $2.26M | (m) | 34.88× |
| 2020-06-30 | $22.30M | $59.74M | $17.75M | $3.90M | (m) | (m) | $1.73M | (m) | 0.37× |
| 2019-12-31 | $37.47M | $8.16M | $20.61M | $16.38M | (m) | (m) | $1.88M | (m) | 4.59× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |